tbuckley/cabot-search huggingface dataset:
SAT0246 Comparison of Level of Fatigue and Disease Correlates in Patients with Rheumatoid Arthritis and Systemic Sclerosis:
Authors: K. Gok, K. Erol, G. Cengiz, S. Ozgocmen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) and systemic sclerosis (SScl) are two different forms of connective tissue diseases associated with significant morbidity. While fatigue is not required for a diagnosis of RA or SScl persistent fatigue is an important clinical problem which may interfere with loss of functioning and health related quality of life (HRQoL) and contribute to the increased disease burden. Several studies compared these two diseases in terms of clinical, laboratory and imaging aspects, however level of fatigue has not been evaluated comparatively. <h3>Objectives</h3> The aim of this study was to compare levels of fatigue in RA and SSc and to assess potential influence of fatigue on clinical variables. <h3>Methods</h3> Patients meeting the ACR/EULAR criteria for SSc and RA with an age more than 18 were consecutively recruited. Patients with a prior diagnosis of psychiatric disorders or fibromyalgia or taking medications for these disorders, or with uncontrolled diabetes, neurological disorders or taking any kind of biologic agents were excluded. Patients were examined and evaluated for disease specific and generic outcome measures including disease activity parameters, physical functions, psychological status and health related quality of life (HRQoL) measures. Level of fatigue was assessed by Fatigue Severity Scale (FSS) and Multidimensional Assessment of Fatigue (MAF) scale. These were interviewed by the same experienced physician who was blind to clinical data. <h3>Results</h3> Fifty patients (44 F, 6 M) with SSc and fifty-one (45 F, 6 M) with RA were included. Patients had similar age and similar gender, educational and smoking status, as well as functioning and HRQoL. However, patients with RA declared higher levels on VAS-pain (p=0.012), and higher body mass index than patients with SSc (p&lt;0.0001) and lower distances in 6-minute walking test (p=0.002). Levels of fatigue which were assessed by VAS, FSS and MAF were quite similar between patients with RA and SSc. Levels of fatigue, measured by different scales, were significantly correlated with physical functions and HRQoL measures and psychometric variables in both groups, however the correlation coefficients were relatively higher in patients with RA. <h3>Conclusions</h3> Fatigue is a major problem in patients with RA and SSc. This is the first report comparing these two diseases in terms of fatigue and its correlates. Patients with RA and SSc should be carefully evaluated for fatigue by using valid scales and the impact of fatigue on clinical measures should not be overlooked. <h3>Disclosure of Interest</h3> None declared
Transplantation of Immunodeficient Mice with Chronic Myeloid Leukemia (CML) Cells from Chronic Phase Patients Reveals a Hierarchy of CD34+ Aldehyde Dehydrogenase-Positive Cells with Short- and Long-Term Repopulating Activity and Transient Responsiveness to Imatinib Mesylate in Vivo.
Authors: Oliver Christ, Wolfgang Eisterer, Xiaoyan Jiang, Emily Pang, Karen Leung, Clayton Smith, Allen C. Eaves, Connie J. Eaves
Journal: Blood (2004)
Association of Genetic Polymorphisms of Glutatione-S-Transferase Genes and Overall Response/Clinical Features in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab.
Authors: Pamela Oliveira-Souza, Debora Levy, Hamen G Booij, Felipe Vieira Rodrigues Maciel, Juliana Pereira, Sergio Paulo Bydlowski
Journal: Blood (2009)
SAT0440 Radiologic Progression of Distal Interphalangeal Joint Osteoarthritis in Rheumatoid Arthritis
Authors: C. Lechtenboehmer, V.K. Jaeger, D. Kyburz, U.A. Walker, T. Hügle
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Distal interphalangeal (DIP) joint osteoarthritis (OA) is a disorder associated with female sex and age and is considered as unrelated to rheumatoid arthritis (RA). The long term radiologic course of DIP OA in patients with RA is unknown. <h3>Objectives</h3> To investigate the prevalence and demographic characteristics of DIP OA progression in RA patients. <h3>Methods</h3> RA patients of the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) cohort, who had at least two subsequent hand radiographies taken between November 1983 and October 2014 were analysed. DIP joints (II-V) were scored for the radiologic presence and severity of osteophytes, subchondral sclerosis, joint space narrowing and erosions according to the modified Kellgren Lawrence Score (KLS). <h3>Results</h3> 2890 (35%) patients out of 8280 of the SCQM RA cohort fulfilled the inclusion criteria. Their mean age was 57.5 years (standard deviation (SD) 10.5), 76% were female, 78% were rheumatoid factor positive and 69% were ACPA positive. At baseline, the mean disease duration was 9.7 years (SD 8.5). The mean follow-up between the first and last radiography was 5.4 years (SD 3.2). Baseline radiographies showed osteophytes in 21% of 21,333 DIP joints, joint space narrowing in 13%, osteosclerosis in 9% and erosions in 1%. The KLS was 1 in 13% of DIP joints, 2 in 22%, 3 in 4% and 4 in 2% at baseline radiographies. The KLS increased in 12% of DIP joints during the radiologic follow-up, decreased in 2% and remained stable in 86% of DIP joints. Female sex (p&lt;0.001), age&gt;55 years (p=0.005) and a negative rheumatoid factor (p=0.049) were associated with OA progression. <h3>Conclusions</h3> Known risk factors for DIP OA were also associated with its radiologic progression in RA patients. Radiologic progression and erosions in DIP OA are low in this cohort, potentially due to RA treatment. <h3>Disclosure of Interest</h3> None declared
Impact of the built environment on self-rated health and wellbeing and other health behaviours of people in social, intermediate, and market-rent accommodation: baseline characteristics of ENABLE London Study participants
Authors: Bina Ram, Claire M Nightingale, Alicja R Rudnicka, Aparna Shankar, Mohammed T Hudda, Anne Ellaway, Ashley R Cooper, Angie Page, Daniel Lewis, Steven Cummins, Billie Giles-Corti, Peter H Whincup, Derek G Cook, Christopher G Owen
Journal: The Lancet (2016)
SAT0137 High Disease Activity and Glucocorticoid Use Are Associated with Increased Risk of Mycobacterium Tuberculosis Infection in Rheumatoid Arthritis
Authors: S. Chaiamnuay, K. Chullapant
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) increased risk of Mycobacterium Tuberculosis Infection (TB). Risk of TB infection in RA patients from Thailand, the country with moderate prevalence of TB infection (137/100,000 in general population) has not been studied. <h3>Objectives</h3> The aim of this study was to determine incidence and factors related TB infection in RA patients from Thailand. <h3>Methods</h3> All patients were diagnosed with RA according to American College of Rheumatology (ACR) 1987 and/or ACR and European league of Rheumatology 2010 between 2000 and 2015. Twenty Cases of TB infection diagnosed after having RA were identified. TB infection was diagnosed by WHO 2013 revision definition and confirmed by physicians. Four age and sex matched controls were selected from 355 RA patients from Thai Army Rheumatoid Arthritis Cohort. Demographic data, RA disease associated factors and risk factos for TB infection were collected. Incidence rate was calculated by incidence density. Univariable and multivariable analyses were performed to identify factors associated with TB. <h3>Results</h3> Twenty-nine TB cases and 116 controls were included and 85.60% were female. The mean age ± SD was 64.75±11.06 years and mean disease duration ± SD was 12.79±7.15 years. Rheumatoid factor and anti-citrullinated protein antibody were positive in 75.23 and 68.95%, respectively. Most patients (93.18%) were treated with synthetic DMARDs. The combination of biologic and synthetic DMARDs was used in 7.58% of the patients. Incidence of TB infection was 2,180/100,000 person-year. Cases were more likely to have higher disease activity, use higher dose of methotrexate, use higher dose of leflunomide and use higher dose of glucocorticoid than controls. The means ± SD of Disease activity28 score (DAS28), dose of methotrexate, dose of leflunomide and dose of glucocorticoid in cases and control were 5.26 ±1.73 vs 4.45 ±1.51 (p=0.027), 9.84 ±6.02 vs 6.47 ±5.62 mg/week (p=0.03), 15±9.26 vs 6.55±7.53 mg/day (p=0.06) and 6.17±5.18 vs 1.15±2.06 mg/day (p=0.005), respectively. In multivariate regression analysis, only high DAS28 and current use of prednisolone were independently associated with TB infection (Odd ratio, 95% CI of 4.95, 1.15–8.36 and 1.23, 1.04–1.44, respectively). <h3>Conclusions</h3> Incidence of TB infection in RA in this study was very high compared to general population in Thailand and other Asian countries such as Hong Kong and Korea. High RA disease activity and the use of glucocorticoid are independently associated with TB infection. <h3>References</h3> Navarra S et al. International Journal of Rheumatic Diseases 2014; 17: 291–298. Mok CC, et al. International Journal of Rheumatic Diseases 2014;17 Suppl 3:1–8. Seong SS, et al. Kim EM, et al. J Rheumatol 2011;38:2218–2230. <h3>Disclosure of Interest</h3> None declared
Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling
Authors: Hirokazu Miki, Masahiro Abe, Kumiko Kagawa, Asuka Oda, Hiroe Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Takeshi Harada, Shiro Fujii, Shingen Nakamura, Ayako Nakano, Kyoko Takeuchi, Shuji Ozaki, Yukimasa Shiotsu, Masaki Ri, Shinsuke Iida, Toshio Matsumoto
Journal: Blood (2011)
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment
Authors: Matilde Y Follo, Sara Mongiorgi, Cristina Clissa, Carla Filì, Chiara Colombi, Michele Baccarani, Giovanni Martinelli, Domenico Russo, Lucia Manzoli, Alberto M Martelli, Carlo Finelli, Lucio Cocco
Journal: Blood (2010)
FRI0300 Correlations of Δ High-Resolution Computed Tomography (HRCT) Score with Δ Clinical Variables in Early Systemic Sclerosis (SSC) Patients:
Authors: S. Wangkaew, J. Euathrongchit, P. Watanawittawas, N. Kasitanon, W. Louthrenoo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The high-resolution computed tomography (HRCT) score showed correlation with % predicted Forced Vital Capacity (%pFVC) in our previous study<sup>1</sup>. However, the correlations of the delta (Δ) HRCT scores with Δ %pFVC and Δ clinical variables have not been reported. <h3>Objectives</h3> To evaluate the correlation of the Δ HRCT scores with Δ %pFVC, Δ Modified Rodnan Skin Score (MRSS) and Δ ESR in patients with early SSc. <h3>Methods</h3> We used an inception cohort of early SSc patients seen at the Rheumatology clinic, Chiang Mai University, between January 2010 and June 2014. All patients underwent HRCT at study entry and every 12 months thereafter. The extent of ground glass (GG), lung fibrosis (Fib), bronchiectasis (B) and honeycombing (HC) was scored and then were aggregated to produce a total (t) HRCT score<sup>1</sup>. Thirty-one SSc patients who underwent pulmonary function test within 12 weeks of their corresponding HRCT were identified. The Δ HRCT score (the difference between the last visit and the baseline HRCT score) along with their corresponding clinical variables were used for analysis. Data abstracted include the HRCT scores: total (t)-GG, t-Fib, t-B, t-HC and t-HRCT; %pFVC; MRSS; and ESR. <h3>Results</h3> Mean±SD age and disease duration (from non-Raynaud9s phenomenon to undergo first HRCT) were 52.2 ± 8.8 years and 11.7 ± 7.1 months, respectively. Seventeen (54.8%) patients were female and 20 (64.5%) were classified as diffuse cutaneous SSc. Mean±SD interval between the two HRCT tests was 16.0 ± 7.2 months. The mean±SD baseline t-GG, t-Fib, t-B, t-HC and t-HRCT scores were 3.2± 3.3, 4.0±3.5, 2.4±3.3, 0.7 ±2.2 and 10.3±10.3, respectively. The mean ±SD baseline %pFVC, MRSS and ESR were 69.0±15.9, 15.4±9.9 and 34.0±25.3, respectively. The mean ±SD absolute Δ HRCT scores were: t-GG, -0.5±2.1 (range -6.0 to 3.0); t-Fib, 0.3±1.9 (range -7.0 to 5.0); t-B, 0.5±1.2 (range -2.0 to 4.0); t-HC, 0.3±0.8 (range 0 to 3.0); t-HRCT, 0.7±3.8 (range-9.0 to 10.0). The mean ±SD absolute Δ clinical variables were: % of predicted FVC, 4.8 ±12.8 (range -33 to 26); MRSS, 4.9± 6.5 (range -17.0 to 8.0); ESR, -5.8 ±22.3 (range -60 to 58). Spearman rank correlations coefficient between the mean absolute ΔHRCT scores and the other variables were (N=31): <h3>Conclusions</h3> In this study, the HRCT scores were fairly stable over the first two years of patients with early SSc; while %pFVC, MRSS and ESR showed relatively more change over the times. We found significantly negative correlation between Δ t-HC and Δ ESR. However, no significant correlations of Δ HRCT scores with Δ %pFVC and Δ MRSS were observed. Further longer study duration with larger study population is needed to confirm our findings. <h3>References</h3> Wangkaew S, et al. Mod Rheumatol. 2015 Dec 23:1–6. <h3>Disclosure of Interest</h3> None declared
AB1043 The Relationship among Pain Sleep Disorders and Smoke in Patients Who Access for The First Time in A Rheumatology Unit
Authors: R. Tirri, R. Ferrara
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pain is the most frequent manifestation of musculoskeletal conditions. Sleep disorders are common in a variety of rheumatologic diseases (1). The cigarette smoking is associated with exacerbated pain intensity and related symptoms (2,3). <h3>Objectives</h3> This study aimed to investigate the relationship between pain,sleep disorders and current smoker status in an Italian population sample who suffered by muscoloskeletal conditions. <h3>Methods</h3> A total of 978 patients were consecutively included from december 2014 to december 2015.Partecipants were assessed by Visual Analogic Scale (VAS) for pain intensity and by questions about sleep duration for sleep disorders (&lt;6 h short sleeper;6–9 h normal sleeper, &gt;9 h long sleeper) Smoker o non smoker current status was determinate by using one question. We considered patients without pain as controls. <h3>Results</h3> The mean age of partecipants was 52,7 years in wich most of them (86%) was female. Strong correlation (p=0.0058) was found between high pain, current smoker and short sleeper status. A correlation (p=0,085) was found between high pain, no current smoker and short sleeper status.High pain was strongly associated with short sleeper satus.(p=0,0078) <h3>Conclusions</h3> Short sleeper status is very prevalent in patients suffered by a musculoskeletal condition with high pain.Current smoker status is an independent variable. <h3>References</h3> Abad VC et al.Sleep and Rheumatologic disorders. Sleep Med Rev. 2008 Jun;12(3):211–28. Review Ditre JW. Pain as a motivator of smoking:effect of pain induction on smoking urge and behavior. J Abnorm Psychol 2008 May;117(2): 467–47 BA Stipelman et al. J Behave Med (2013)36:539–548 <h3>Disclosure of Interest</h3> None declared
Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors
Authors: Mauricette Michallet, Mohamad Sobh, Aline Praire, Frederic Garban, Claude Eric Bulabois, Ibrahim Yakoub-Agha, Valerie Coiteux, Remy Dulery, Pierre-Simon Rohrlich, Faezeh Legrand, Laurence Clement, Stephane Morisset, Giovanna Cannas, Marie Y. Detrait, Fiorenza Barraco, Franck E. Nicolini, Olivier Hequet
Journal: Blood (2014)
Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum
Authors: B.C. Wu, E.D. Patel, A.G. Ortega-Loayza
Journal: British Journal of Dermatology (2016)

Pyoderma gangrenosum (PG) is a rare autoinflammatory condition in which the alteration of neutrophil function and the innate immune response play key roles in its pathogenesis. Cases of PG have been reported in patients being treated with certain medications, which may help us to understand some of the possible pathways involved in the aetiology of PG. The aim of this review is to review the cases of PG triggered by certain drugs and try to thoroughly understand the pathogenesis of the disease. To accomplish this, a PubMed search was completed using the following words: pyoderma gangrenosum, neutrophilic dermatosis, pathophysiology, drug‐induced pyoderma gangrenosum. In total, we found 43 cases of drug‐induced PG. Most of them were caused by colony‐stimulating factors and small‐molecule tyrosine kinase inhibitors. We propose that drugs induce PG through various mechanisms such as dysfunctional neutrophil migration and function, dysregulated inflammatory response, promotion of keratinocyte apoptosis and alteration of epigenetic mechanisms. PG is a rare condition with complex pathophysiology and drug‐induced cases are even more scarce; this is the main limitation of this review. Understanding the possible mechanisms of drug‐induced PG, via abnormal neutrophil migration and function, abnormal inflammation, keratinocyte apoptosis and alteration of epigenetic mechanisms would help to better understand the pathogenesis of PG and ultimately to optimize targeted therapy.
THU0413 Utility of The Spade Tool To Identify Axial Spondyloarthritis in Patients with Chronic Backpain
Authors: S. Habibi, S. Doshi, R. Sengupta
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Many referral strategies have been devised to optimize the early diagnosis of axial spondyloarthritis (AxSpA). These result in the diagnosis of AxSpA in 30 to 40% of patients. Strategies to reduce the delay in diagnosis of AxSpA and optimise the appropriateness of referrals to secondary care should be explored. The Spondyloarthritis Diagnosis Evaluation (SPADE) tool (www.spadetool.co.uk has been designed to assist healthcare professionals define the probability of axial spondyloarthritis (AxSpA) in patients &lt;45 years of age with chronic back pain and no definite changes on radiographs. The probability of AxSpA derived from the 9SPADE Tool9 is displayed on a chart with clear instructions for the user on what action should be taken next. <h3>Objectives</h3> To assess the performance of the SPADE tool in the secondary care setting. <h3>Methods</h3> The RNHRD runs a weekly Early Back Pain (EBP) clinic. Data on all patients (AxSpA and Mechanical back pain) has been collected. The SPADE tool which consists of questions pertaining to clinical features, CRP, HLA-B27 and MRI findings was applied on all EBP patients utilizing data they were referred with (before Specialist advised investigations- MRI scan results) to obtain the probability of SpA as one of the 4 categories: Category 1-improbable, category 2-additional tests needed (HLA-B27 or MRI, consider referral to a specialist), category 3 (probable SpA) and category 4 (definitive SpA). A physicians diagnosis of AxSpA was used as the gold standard. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were estimated using observed ratios of patient numbers from this sample. 95% CIs on the NPV were generated by assuming a binomial model for x, where x is the number of patients with SpA who are not referred at a given SPADE threshold. <h3>Results</h3> N=87 (49 males); 44 (50.5%) had SpA subsequently diagnosed; 6/27 in category 1, 26/44 in category 2, 5/7 in category 3 and 7/9 in category 4. Estimates of PPV, NPV, sensitivity and specificity obtained by using each of the SPADE categories as a threshold for referral are given in the table. <h3>Conclusions</h3> The SPADE tool is a valuable resource to assist clinicians define the probability of SpA in patients with chronic back pain. The high NPV, especially with the referral threshold set at 2 or 3, implies that the test is most useful in ruling out SpA. Note that the prevalence of AxSpA in this sample is likely to be higher than in the target population (primary care), meaning that these estimates of NPV are likely to be underestimates. The tool needs to be validated in a primary care setting. <h3>Acknowledgement</h3> The funding for the SPADE tool was provided through a Medical Education grant from Abviee <h3>Disclosure of Interest</h3> None declared
The origin of fibrogenic myofibroblasts in fibrotic liver
Authors: Tatiana Kisseleva
Journal: Hepatology (2016)

Liver fibrosis results from chronic liver injury of different etiologies. It is characterized by dysregulation of physiological remodeling, activation of myofibroblasts, and formation of a fibrous scar. Myofibroblasts develop contractile functions and secrete the extracellular matrix proteins that form this fibrous scar. Myofibroblasts are not present in the normal liver but activate and proliferate in response to injury and inflammation. This review summarizes the understanding and controversies on the contribution of cell populations to the myofibroblasts in liver fibrosis. (H epatology 2017;65:1039‐1043).
THU0336 Outcomes in Patients with Ischemic Stroke Regarding Titer and Persistence of Antiphospholipid Antibodies:
Authors: J.Y. Pyo, S.W. Lee, J.J. Song, S.-K. Lee, Y.-B. Park
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Stroke and transient ischemic attack (TIA) are the most common neurologic manifestation of antiphospholipid syndrome (APS). The international consensus criteria for APS classification require persistent antiphospholipid antibodies (aPL) positivity (at least 12 weeks apart) and medium or high titer for anticardiolipin antibody (aCL) associated with clinical manifestations [1]. To confirm the diagnosis of a patient who comes with stroke/TIA and positive aPL as definite APS, we serially check the positivity of aPL in addition to titer of aCL. However, significance of persistence and moderate or high titer of aPL on the clinical relevance is not identified. <h3>Objectives</h3> To evaluate the effect of persistent and medium or high titer of aPL positivity on recurrence in patients with ischemic stroke/TIA. <h3>Methods</h3> We reviewed medical records of 99 patients with ischemic stroke/TIA who had at least one or more positive aPL (ie, positivity for anticardiolipin antibodies [aCL], β<sub>2</sub>-glycoprotein I antibodies [β<sub>2</sub>-GPI], lupus anticoagulant antibodies [LA]). We divided these patients into two groups according to the most recent revised classification (Sydney consensus conference), and designated as “definite APS” who fulfilled the laboratory criteria, and “aPL carriers” who had transient or low titer aPL. We compared the subsequent ischemic stroke/TIA events between the two groups. <h3>Results</h3> Of the 99 patients, 46 (46%) were classified as definite APS and 53 (54%) as aPL carriers. There was no increased risk of subsequent ischemic/TIA events in definite APS group compared with aPL carriers group. The overall event was 14 (30.4%) in APS group and 16 (30.2%) in aPL carriers group during 60.4 months and 43.8 months follow up period respectively. 38 patients were having anticoagulation for treatment and 60 patients were on anti-platelet treatment without anticoagulation, but there was no difference on recurrence events regarding the treatment. Among definite APS group, there was no difference in recurrence events according anticoagulation vs anti-platelet agent. <h3>Conclusions</h3> The persistence and medium or high titer of aPL enables to diagnose APS in ischemic stroke/TIA patients, but does not predict increased risk for subsequent ischemic stroke/TIA. <h3>References</h3> Rand JH. The antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2007:136–142 <h3>Disclosure of Interest</h3> None declared